Pre-Clinical Assessment of the Potential Intrinsic Hepatotoxicity of Candidate Drugs by van Tonder, Jacob John et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Pre-Clinical Assessment of the Potential
Intrinsic Hepatotoxicity of Candidate Drugs
Jacob John van Tonder, Vanessa Steenkamp and
Mary Gulumian
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54792
1. Introduction
1.1. The cost of new drugs and need to streamline drug development
Innovation is fundamental to discovering new drugs for the variety of human conditions that
exist. It is also one of the key requirements for any pharmaceutical organization that wishes
to gain a competitive edge. The pharmaceutical industry is profit-driven because it has to fund
its own drug innovation, which highlights why research and development (R&D) forms the
backbone of this industry. According to the CEO of the Pharmaceutical Research and Manu‐
facturers of America (PhRMA), John Castellani, member companies of PhRMA spent a record
US$ 67.4 billion on R&D in 2011. This is approximately 20% of generated revenue, which is 5
times more than the average manufacturing firm invests into R&D [1]. The pharmaceutical
sector was responsible for 20% of all R&D expenditures by U.S. businesses in 2011 [2]. The
aforesaid figures do not describe global R&D expenditures, but serve to give some indication
of the astronomical contributions that are annually devoted by the pharmaceutical industry
to drug development.
Substantial fiscal investments are made against the backdrop of enormous investment risks.
It is estimated that only 5 of every 10 000 compounds explored will make it to clinical trials [1].
Although the likelihood that an investigational new drug in clinical testing reaches the market
has increased over the past couple of decades to 16%, the probability is still low. Furthermore,
of those that do get approved, only 2 or 3 out of every 10 drugs recover their full pecuniary
investment [1]. The stakes are incredible and the strain on the industry as a whole is overt. In
2011 the world's largest research-based pharmaceutical company, Pfizer, closed its R&D centre
located in the U.K. owing to financial viability concerns. In an attempt to dissuade some of the
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financial pressures, many companies have opted for mergers to either maintain existing
pipelines or acquire new development opportunities [3].
A fairly regular citation estimates the out-of-pocket, pre-approval cost per drug developed to
be more than US$ 800 million [4]. Estimations reported in peer-reviewed literature ranges from
US$ 391 million [5] to US$ 1.8 billion [6]. Evident from literature is the fact that the estimates
increase over time, in other words, the cost of developing drugs is escalating, which implies
ever-increasing financial pressures on industry.
Two of the most prominent concerns for the pharmaceutical industry are patent expirations
and attrition rates. Patent expirations result in decreased revenue generation and, as stated,
this industry is profit-driven, meaning that diminished earnings cripple the R&D of an
organization. Not only does this predict deterioration for a pharmaceutical company, but
decreased R&D output also slows the production of new drugs. This also has a major impact
on healthcare. It is estimated that in the U.S. a new case of Alzheimer's develops every 68
seconds [7]. Using these figures, more than 460 000 new cases of Alzheimer's will develop each
year the approval of an effective new drug is delayed. Whereas patent expirations prune
generated revenues, attrition rates affect the opposite side of the equation, needlessly raising
the cost of developing new drugs. Attrition rates are high (Figure 1). A chemical entity that
reaches phase I clinical trials has a 71% chance of reaching phase II clinical trials. Those
chemical entities that do reach phase II trials have only a 31% chance of entering phase III trials.
Further compounding the issue are rising failure rates in phase III trials [4]. Attrition drives
development costs for two reasons: 1) monetary investments into failed ventures are lost and
2) failing development programs occupy resources and time that could otherwise be spent on
drug candidates that would eventually succeed to be approved for marketing.
Figure 1. The probability that a chemical entity under development will progress from one clinical phase to the next. Can‐
didate drugs have only a 22% chance of completing clinical development prior to review by regulatory authorities [4].
Together, patent expirations and drug attrition add enormous strain on new drug develop‐
ment, in a cumulative way inhibiting productivity and output of the entire R&D process. An
article recently published by Forbes offers some perspective on the impact of attrition on
development costs [8]. According to this article, AstraZeneca has been plagued by develop‐
ment failures, which escalated their average cost to develop a new drug to US$ 12 billion. In
comparison, for Eli Lilly the average cost of developing a new drugs is estimated at only US$
4.5 billion. The difference in development cost between the two companies can be attributed
to the difference in approval rates of new drug i.e. less failures [8].
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The average times, from the start of a particular phase to entering the next phase, are 4.3 years
for pre-clinical development and 1.0, 2.2 and 2.8 years for phase I, II and III trials, respectively.
Regulatory perusal adds another 1.5 years to the entire process [4]. Collectively, the duration of
drug development from initiation of clinical testing until drug approval is estimated at 7.5 years
[4]. Including pre-clinical development, it takes, on average, 10 - 15 years to develop a new drug
from its discovery to regulatory approval [1,4] (Figure 2). A study that investigated the reduc‐
tion in costs associated with drug development with improved productivity of the process re‐
ported that a 5% reduction in total development time will decrease development costs by 3.5%
[9]. Although this may not sound like much, 3.5% of US$ 1 billion is a substantial saving. The
study also emphasized the reduction in costs if decisions to terminate unproductive develop‐
ment programs are shifted to earlier phases of the discovery process. For example, the study es‐
timated that if a company manages to shift a quarter of its decisions to terminate from phase II to
phase I, it would save US$ 22 million [9]. Again, it relates back to why attrition drives develop‐
ment costs. Making the decision to terminate (a development program) earlier would stop fur‐
ther investment into unfruitful programs and free resources to promote approval ratings.
Figure 2. Average duration (in years) of different phases of drug development [4]. Reducing phase duration will re‐
duce associated development costs.
Industry continuously struggles to bring new drugs to the market, despite the process being
overextended, costly and particularly uncertain of success. Over the last decade, overall drug
development time has increased by 20% and the rate of approval of new chemical entities has
dropped by 30% [10]. There is a mounting need to nurture output from the drug development
process. Minor restructuring and streamlining of this process is required to increase its
productivity and alleviate some of the financial pressures that drug developers experience.
One area in particular where pruning of this process is overdue is the early pre-clinical
detection / prediction of potential hepatotoxic chemical entities.
2. Attrition due to hepatotoxicity
Drug-induced liver injury (DILI) is a challenge for both the pharmaceutical industry and
regulatory authorities. The most severe adverse effect that DILI may lead to is acute liver
failure, resulting in either death or liver transplant. Of all the cases of acute liver failure in the
U.S., between 13% and 50% can be attributed to DILI [11,12]. Without a doubt there is great
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concern for the safety of consumers exposed to drugs that may cause DILI because patients
have only one liver. For this reason, government and the public put pressure on regulatory
authorities to establish safer drugs [13]. However, if regulatory authorities unnecessarily raise
safety standards without scientific evidence, this will discourage drug development because
of attrition, which is predominantly unwanted when considering the current scenario where
fewer antimicrobials are being developed alongside increased antibiotic resistance.
A prevailing issue in drug development is the attrition of new drug candidates. Between 1995
and 2005, a total of 34 drugs were withdrawn from various markets (Table 1) and the reason
for withdrawal in the majority of cases was hepatotoxicity [14]. Hepatotoxicity is the leading
cause of drug withdrawals from the marketplace [15-17]. Examples include the monoamine
oxidase inhibitor, iproniazid, the anti-diabetic drug, troglitazone, and the anti-inflammatory
analgesic, bromfenac, all of which induced idiosyncratic liver injury. Iproniazid, the first
monoamine oxidase inhibitor released in the 1950's, was probably the most hepatotoxic drug
ever marketed [16]. Troglitazone was available on the U.S. market from March 1997. By
February 2000, 83 patients had developed liver failure, of which 70% died. Of the 26 survivors,
6 required liver transplants [18]. While on the market, troglitazone accrued approximately US
$ 700 million per year [14]. Withdrawals of lucrative drugs like troglitazone diminish return
on investments and threaten further R&D.
Of all classes of drugs, non-steroidal anti-inflammatory drugs (NSAIDs) have had one of the
worst track records regarding hepatotoxicity. Benoxaprofen and bromfenac are two NSAIDs
that were withdrawn from public use after reports of hepatotoxicity [16,19]. Benoxaprofen was
withdrawn in 1982, the same year that it was approved [16]. Bromfenac was predicted to earn
around US$ 500 million per year [14].
Although diclofenac is widely used to treat rheumatoid disorders, approximately 250 cases of
diclofenac-induced hepatotoxicity have been reported. In perspective, DILI caused by
diclofenac has an incidence of 1-2 per every million prescriptions [20,21], being high enough
that a considerable amount of literature has been generated warning against diclofenac-
induced hepatotoxicity. Between 1982 and 2001 in France, more than 27 000 cases of NSAID-
induced liver injuries were reported. Clometacin, and silundac were the NSAIDs with the
highest risk of DILI. Over the same peroid approximately 2100 cases of NSAID-induced liver
injuries were reported in Spain, with the main culprits being droxicam, silundac and nimesu‐
lide [22]. Acetaminophen (a.k.a. paracetamol) must be the most notorious of all the NSAIDs,
if not all drugs, when it comes to DILI. Its mechanism of hepatotoxicity is better understood
than its therapeutic mechanism of action. Fortunately, acetaminophen has a substantial
therapeutic index and copious amounts need to be administered before the liver will not be
able to manage its onslaught anymore [23].
Troglitazone was available on the U.S. market for three years before withdrawal, during which
time it was used by almost 2 million patients, realising some return on investment [18].
Ximelagatran, on the other hand, was in the very late stages of development when its fate was
sealed. In fact, AstraZeneca had already applied at the EMEA for marketing approval when
the company withdrew all applications due to concerns over the hepatotoxic potential of the
drug [24]. Although this drug did reach the market in France, the U.S. FDA was not prepared
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to grant approval and the drug was never marketed in the U.S. [25]. Ximelagatran, which was
the first orally available thrombin inhibitor that would have replaced the troublesome warfarin
as an oral anticoagulant, serves as a good example where huge investments were made to get
the drug to market, but a return on investment was never realised. This example emphasizes
the necessity for improved methodologies to predict intrinsic hepatotoxicity more accurately



















Table 1. Drugs that have been withdrawn from international marketplaces between 1995 and 2005 due to associated
hepatotoxicity.
Examples of other drugs that were never marketed in the U.S. because of hepatotoxicity include
drugs such as ibufenac, perhexilene and dilevalol. There are also drugs for which the use /
application has been limited because of possible DILI. These include the drugs isoniazid,
pemoline, tolcapone and trovafloxacin [15]. A big question that remains a challenge for
regulatory authorities is how rare or mild does hepatotoxicity have to be for a drug to be
approved and to remain on the market? [13] Undoubtedly, DILI has a sizeable influence on
drug development output. Pre- and post-marketing attrition as a result of DILI causes further
financial stresses for those in the industry. Limiting attrition to the early phases of drug
development can only be beneficial. Both the pharmaceutical industry and regulatory author‐
ities agree that there is a great need for improved methodologies and strategies to accurately
assess the hepatotoxic potential of compounds, earlier in the drug development process [13,26].
3. Safety pharmacology and current practices used to detect hepatotoxicity
Distinct from pharmacology proper, which examines the desired effects and kinetics of a
particular drug, safety pharmacology identifies and characterises secondary adverse pharma‐
cological and toxicological effects of potential drugs, mainly through the use of established
animal models [27]. Regulatory authorities require that certain minimal safety pharmacology
examinations be completed before a new investigation drug application will be approved.
These international regulatory guidelines were compiled by the International Committee for
Harmonization (ICH) in the documentation covering topic S7. The ICH S7A and ICH S7B
guidelines have been in effect since 2000 and 2001, respectively [27].
At present, the attention of pre-clinical safety pharmacology investigations is drawn to three
physiological systems: the cardiovascular system, the respiratory system and the central nerv‐
ous system (for compounds that may cross the blood-brain barrier). Effects on the cardiovascu‐
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lar system are of great concern because 1) it is a system often found to be affected and 2) due to its
redundancy (organisms relevant to drug development have only one heart). Like the heart, the
respiratory system is of concern because it is essential to the immediate survival of the organism.
Hepatic safety does not form part of the core battery of pre-clinical tests performed for initial safe‐
ty pharmacology. The EMEA have published draft guidance on the non-clinical assessment of
hepatotoxic potential [28]. This draft amounted to a clinical white paper [29], however, no regula‐
tions are set in place yet. This initial draft may demonstrate the future intent of regulatory authori‐
ties. If this is the case, not only is it worthwhile for the pharmaceutical companies to consider
improved pre-clinical evaluation of hepatotoxic potential for their own profit, but it may soon be
required as part of their investigational drug applications before first-in-human trials.
Currently, in vivo screening for hepatotoxicity during both the pre-clinical animal testing and
clinical phases of the development process forms the basis of hepatic safety testing. However,
from an extensive study on available literature, Biowisdom, a healthcare intelligence company,
estimates that between 38% and 51% of compounds showing liver effects in humans do not
present similar effects in animal studies including both rodents and non-rodents [30]. The main‐
stay clinical chemistry can be used to detect certain types of hepatic injury. For example, the ami‐
notransferases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), can be
used to identify hepatocellular injury, whereas levels of bilirubin and alkaline phosphatase can
be used to assess hepatobiliary health [28,31]. Of the two aminotransferases ALT is by and large
superior at predicting hepatocellular injury for two reasons: 1) ALT is a more sensitive signal
than AST because it is found in higher concentrations in the cytosol of hepatocytes and 2) ALT is
also more specific to the liver than AST as AST is normally also present in the blood, skeletal mus‐
cle and heart [32]. The ratio of ALT/AST has been found useful to differentiate, to some degree,
between different types of liver injury. An ALT/AST ratio >2:1 may be indicative of an alcoholic
type liver injury, whereas a ration of 1:1 could point to non-alcoholic steatohepatitis a.k.a. NASH
[33]. Logistic regression analysis on 784 reports of DILI received by the Swedish Adverse Drug
Reaction Advisory Committee between 1970 and 2004 found that, in combination, an AST/ALT
ratio > 1 and bilirubin > 2 × upper limit of normal (ULN) had a higher positive predictive value
than either AST in combination with bilirubin or ALT in combination with bilirubin [34]. The
"Rezulin rule" was coined to describe the fact that the more marked any ALT elevations and the
frequency of such elevations during clinical trials, the more significant post-approval hepato‐
toxicity appears to become [35]. Rezulin was the marketing name of troglitazone.
Elevations of > 3 × ULN are considered a sensitive signal of a potential hepatotoxic test
compound. Data from 28 clinical trials (phases II - IV) conducted by GlaxoSmithKline between
1995 and 2005 found elevations in ALT of > 3 × ULN at baseline to be rare, with a prevalence
of 6.265% [36]. A study of Merck clinical trial databases, reported that elevations of ALT or
AST > 3 × ULN had an 83% sensitivity to detect serious liver disease [Senior, 2003]. ALT > 3 ×
ULN has proved a useful threshold for screening for clinically significant DILI from various
hepatotoxic substances. This includes drugs that have been withdrawn from the market due
to hepatotoxicity, such as troglitazone and bromfenac [15]. However, this is not a very specific
signal as increases in aminotransferase levels can also be induced by drugs that do not cause
DILI such as aspirin, statins and heparin [17]. Indeed, the Merck study showed that the
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predictive power of elevations of ALT or AST > 3 × ULN, was only 11% [37]. A separate
manuscript also reported high sensitivity and specificity when using ALT > 3 × ULN, but again
with very low predictive power (only 6%) [38]. Serum ALT or AST levels are therefore a
sensitive screen for possible hepatotoxic side-effects, but not definitive enough to terminate a
drug development program.
Even though it was originally not intended as such, the most successful predictor of hepato‐
toxicity is “Hy’s law”, which is based on the original observations made by Dr. Hyman
Zimmerman. It was described by Dr. Zimmerman as "clinical jaundice" and its modern
application has proved valuable in being able to predict idiosyncratic hepatotoxicities brought
about by drugs / potential drugs such as troglitazone and dilevalol. A more recent description
is a state of drug-induced jaundice caused by hepatocellular injury, without any significant
obstructive component [17,35]. Therefore, Hy’s Law is met when:
1. There exists the possibility that a drug (or potential drug) can induce hepatocellular
damage as evident from elevations in serum aminotransferase levels of ≥ 3 × ULN and
2. These elevations are accompanied by elevations in total bilirubin of ≥ 2 × ULN with no
evidence of intra- or extra-hepatic obstruction (elevated ALP) or Gilbert’s syndrome.
It is worth noting that Dr. Zimmerman himself placed some weight on the degree of jaundice as
it often served to predict a negative outcome [35]. Hy's Law is, however, not exclusive to DILI
and if it is met, it is of utmost importance that any other condition(s) that may also cause these
symptoms be excluded before any conclusions are drawn about a potential intrinsic hepatotox‐
in. Such conditions may include viral hepatitis, hypotension or congestive heart failure [17]. Ob‐
viously, the possibility of DILI caused by concomitant drugs should also be excluded.
The incidence of idiosyncratic DILI is generally 1 per 10 000 or less. This makes it exceptionally
difficult to detect idiosyncratic hepatotoxicity due to an investigational drug during clinical
testing, even if several thousands of subjects are studied [39]. Generally, an investigational
drug does not get administered to more than 2000 subjects [33], which makes it unlikely to
detect a single incidence in 10 000. Although it portrays the role of the key predictor of the
hepatotoxic potential of an investigational drug during drug development, Hy's Law falls
short of constituting a "gold standard'" and validation of Hy's Law is much needed, chiefly
with regards to its sensitivity and specificity [35]. Moreover, for the purposes of detecting
potential intrinsic hepatotoxins as early as possible during drug development, the foremost
drawback of Hy’s law is that it requires in vivo testing of the investigational drug. Hy's Law is
therefore not a realistic approach for traditional in vitro testing, the type of testing that can be
applied prior to vast resources being invested into in vivo testing.
4. Methodologies applicable to the early pre-clinical assessment of
potential intrinsic hepatotoxicity
The ultimate goal of research into this field is to establish an in vitro  model or tier of in
vitro  tests  that  is  valid and able to accurately predict  DILI during lead optimisation be‐
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fore any hepatotoxic chemical entity under development unnecessarily progresses into in
vivo studies. Currently, this is still desired as more than 90% of candidate drugs that en‐
ter the clinical phases of drug development still fail to complete development due to in‐
adequate  safety,  pharmacokinetics  or  efficacy  [40].  The  following  sections  will  focus
mainly on in vitro methods as these can be conducted at the lowest expense and at high‐
er throughput than conventional animal studies.
4.1. Cell-based models
4.1.1. Cell cultures
Cell-based models are increasingly used as there is a growing pressure to reduce, refine
and replace the use of  animals  from organisations such as  the European Centre for  the
Validation  of  Alternative  Methods  (ECVAM).  The  three  basic  types  of  cells  used for  in
vitro  toxicity  testing  are  transformed cell  lines,  primary  cells  and  pluripotent  cells.  The
latter  will  be discussed in more detail  later  in the manuscript.  The advantages of  using
transformed cell  lines  include unlimited supply,  no genetic  variation,  which aids repro‐
ducibility and predictive power of an outcome, as well as access to the collective knowl‐
edge gained from global research conducted on the geno- and phenotype of the cell line
in question. The HepG2 cell line, was one of 20 cell lines of human origin that was used
in one of the first international attempts to try and predict in vivo  toxicity through in vi‐
tro  techniques  during  the  Multicentre  Evaluation  of  In  Vitro  Cytotoxicity  (MEIC)  pro‐
gram, initiated by the Scandanavian Society of Cell Toxicology in 1989. The program was
based  on  two  main  assumptions:  1)  there  exists  some  “basal  cytotoxicity”  that  can  be
quantified,  and 2)  in  vitro  methods can be used to  model  some type of  “general  toxici‐
ty”, which is related to the basal cytotoxicity concept [41]. Basal cytotoxicity was defined as
“the toxicity of  a chemical  to basic cellular functions and structures,  common to all  hu‐
man cells”. Although the study lacked some systemic focus, results from the MEIC study
conducted on 50 reference chemicals, demonstrated that in vitro  cytotoxicity assays were
able  to  predict  lethal  human  blood  concentrations  just  as  well  as  rodent  LD50  values
were able to [42].
The use of immortalized human hepatocytes cell lines, like HepG2 cells, were proposed to
overcome limitations of primary human hepatocytes including the scarce availability of fresh
human liver samples, complicated isolation procedures, short life-span, inter-donor variabil‐
ity, and cost. HepG2 cells display morphological features similar to that of liver parenchymal
cells and maintain many functions of in vivo hepatocytes, expressing receptors for insulin,
transferrin, epidermal growth factor and low density lipoprotein [43]. These cells also express
a plethora of cellular products (www.atcc.org). The HepG2 cell line has been used extensively
in research as a model to study cytotoxicity [41], liver lipid metabolism [44], mitochondrial
homeostasis [45,46], oxidative stress [46], gluconeogenesis and glucose uptake [47], to mention
just a few. The applications are very broad and there is a vast collective knowledge about how
these cells behave and respond under specified conditions or when exposed to various
stressors. This must be one of the greatest advantages when using these cells, especially in
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mechanistic studies. However, it is believed that observations made with these cells cannot be
extrapolated to humans as they do not behave as native hepatocytes would because of
discrepancies in drug biotranformation [48]. HepG2 cells are known to express low levels of
cytochrome P450 (CYP) enzymes compared to primary hepatocytes [49,50].
The chief advantage that primary cell cultures have over most perpetual cell lines is that they
are the closest in vitro representation of the in vivo cell type under scrutiny. Hence, primary
hepatocytes are considered the “gold standard” used for predictive toxicology [51]. Unlike
transformed cell lines, primary cultures have a limited growth and life-span and fresh stock
needs to be sourced regularly. This is problematic in itself as human hepatocytes are scarce
and availability sporadic [52]. Another drawback of using primary cultures is the occurrence
of donor-to-donor variability that is introduced into the results, which will decrease the power
of predicting a specific outcome. Although primary hepatocytes initially express higher levels
of metabolic enzymes than transformed cell lines like HepG2 cells [49], in culture their liver-
specific function decrease over time [52].
Two techniques have received attention over the years to try and improve the life-span of
primary hepatocytes in culture. These are sandwich culturing techniques and special medium
formulations. Sandwich culturing techniques address the conformational / spatial discrepan‐
cies between the 2D in vitro and 3D in vivo microenvironments. Hepatocytes are seeded on top
of a layer of either collagen I or matrigel, which mimics in vivo extracellular matrix. An
additional overlay of extracellular matrix is then layered on top of the seeded hepatocytes
[51,53]. Additives to medium formulations attempt to imitate endogenous signalling found in
the in vivo milieu. Serum and corticosteroids are known to affect cultured hepatocyte mor‐
phology. Contradictory to the general thought that adding serum to medium is good for cells,
adding serum to medium that is used for culturing primary hepatocytes will cause the cells to
rapidly deteriorate and lose cytoplasmic integrity and bile canaliculi-like structures. The
corticosteroid, dexamethasone, has also proven helpful in improving primary hepatocyte life-
span when in culture [51]. Culturing primary hepatocytes in a sandwich conformation with
extracellular matrix, no serum and dexamethasone allows the conservation of liver-specific
functionality for several weeks [51].
The problems of low levels of enzyme expression in HepG2 cells and limited life-span of
primary hepatocytes was overcome with the emergence of the HepaRG cell line. These cells
express higher levels of CYP's than HepG2 cells and respond acutely to induction of these
enzymes [50]. HepaRG cells maintain hepatic functions of primary hepatocytes and express
normal levels of liver-specific genes while lacking the inter-donor variability observed with
primary hepatocytes [50,54]. A lot of literature praises HepaRG for the increased metabolic
activity, which allows the in vitro study of drug metabolism using a theoretically unlimited
supply of cells. This is certainly a remarkable advancement for in vitro drug metabolism and
pharmacokinetic (DMPK) studies. However, this is a fairly new cell line (first described in 2002
[55]) and the accrued collective knowledge of this cell line is dwarfed by that of the HepG2 cell
line. A recent study compared the whole genome expression profiles of HepG2, HepaRG
(differentiated and undifferentiated) and primary human hepatocytes to that of human liver
tissues [56]. It was found that in terms of correlation with human liver tissues, the cell cultures
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ranked: primary human hepatocytes > HepaRG > HepG2, which boasts well for the future of
the HepaRG cell line for use in predictive toxicology.
4.1.2. Outcomes and detection methods
Researchers at Pfizer postulate that the poor predictive power of conventional cytotoxicity
assays is related to the endpoint being measured [57]. Cytotoxicity endpoint assays only assess
the final extreme from a series of pathological events that lead to cellular death. Assays that
target such late events are likely to fail in detecting more subtle types of toxicity that develop
after chronic, low-dose exposure to manifest as non-lethal, but definite adverse, complications
[46]. In addition to this, the liver is the only organ in mammals that can fully regenerate after
injury [58], making testing for adaptive changes even more relevant and applicable. An
example of this scenario of subtle toxicity can be found in troglitazone, which exerts sub-acute
hepatotoxicity by acting on a sub-cellular level, disrupting mitochondrial homeostasis. The
mechanism of toxicity of troglitazone was investigated by means of in vitro models [45,59,60],
which emphasizes the role that cell-based test systems can play during early drug develop‐
ment. It is substantially easier to utilize cell-based in vitro models to examine sub-cellular
events, compared to higher levels of biological organization i.e. whole organisms. Cells are the
first level of organization where all the lifeless constituents that comprise a cell, functions
together as an entity, and the first level where disrupted interplay between sub-cellular
components can be evaluated. Cell-based models are more than suitable for the task at hand,
but what is being evaluated using these models is critical to the success of such attempts. Rather
than cell death / survival endpoints, some adaptive / pre-lethal mechanistic endpoints that can
be considered include mitochondrial homeostasis [45,46,61,62], generation of reactive oxygen
species (ROS) [46], lipid peroxidation [62], Ca2+ signalling [62] and inhibition of enzymes and
transporters [63], especially bile acid transporters [63] (Figure 3).
An important tool that was used in the MEIC study, and remains relevant to current method‐
ologies, is that of mathematical modelling. In the MEIC study, researchers employed partial
least squares regression [42]. Mathematical modelling provides a way in which researchers
can combine data from different endpoint assays, thereby allowing them to piece together
underlying associations and correlations observed when drugs (or groups of drugs) affect
normal cellular function. Previous research illustrated how mathematical modelling of
multiparametric data can aid prediction [64]. Seventeen compounds (7 known hepatotoxins
and 10 "unknowns") were subjected to testing using 6 separate endpoint assays monitored
with a fluorescent plate reader. The data was then used to develop 5 prediction models.
Modelling techniques included logistic regression, support vector machines (using several
different kernel functions), decision tree, quadratic discriminant analysis and neural networks.
Discriminant analysis was found to yield the best positive and negative predictive values [64].
In addition, the study highlighted the significance of adequate sample size and careful
consideration and defining of positive and negative test values in the training data set. It is
important to realise that the task of predicting DILI from in vitro studies does not only depend
on the parameters that are measured but also on how the acquired data is reduced and utilised
to reach the critical “go” / “no-go” decision.
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Figure 3. Sequenced outcomes that can be considered for endpoint assays in pre-clinical in vitro assays. Endpoint as‐
says examining adaptive and pre-lethal outcomes can be detected early in the progression towards cellular death and
detect subtle types of toxicity, which late stage endpoint assays fail to do.
As with the study by Flynn and Ferguson [64], high content screening (HCS), which is based
on automated microscopy, also employs fluorescent probes. HCS is one cell-based methodol‐
ogy that has shown promising results in predicting DILI. This methodology has three key
strengths: 1) the ability to simultaneously examine multiple parameters of cellular function, 2)
all parameters can be examined in individual cells, and 3) it has the potential for high-
throughput screening since it is based on a microplate format. Combined, these features
culminate in powerful technology. Testing more than 240 drugs using an HCS platform,
researchers at Pfizer demonstrated that this methodology had overall sensitivity and specif‐
icity of 90% and 98%, respectively, for predicting in vivo hepatotoxicity [46]. When employing
the HCS platform the sensitivity of predicting severely hepatotoxic drugs was 100%, and 80%
for moderately hepatotoxic drugs. This is a noteworthy improvement over the conventional
cytotoxicity assays that showed scores of 20% and 24% for the same predictions [46]. The
authors again stressed the value of chronic, sub-lethal exposure conditions to allow cellular
phenomena to manifest. Recently, a similar study on 61 hepatotoxic and 12 non-hepatotoxic
drugs / compounds examined the same parameters (nuclear morphology, plasma membrane
integrity, mitochondrial membrane potential, and Ca2+ fluxes) with the added parameter of
lipid peroxidation, where scores of > 90% for both sensitivity and specificity were reported [62].
Another fluorescence detection method that has a potential role in early pre-clinical assessment
of intrinsic hepatotoxicity is flow cytometry. Essentially, this method of detection can analyse
the same parameters as fluorometry and fluorescence microscopy. It has not been explored in
as much detail as HCS, but initial reports are positive [65]. There is room for research com‐
paring these different methods of detection and the verdict is still out on which platform
outperforms the rest.
4.2. Profiling technologies
Virtually all responses to toxic insults are accompanied by differential gene expression [66].
Differential gene expression is likely to be accompanied by differential transcription and
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differential protein expression (adaptive responses in Figure 3). On this conceptual basis,
researchers have tried to use profiling technologies such as genomics / transcriptomics and
proteomics to discern between compounds that may or may not induce liver injury and even
between subsets of chemical entities that cause different types of hepatotoxicity like necrosis,
steatosis and cholestasis [67].
The sensitivity of genomics experiments is high enough to detect subtle changes in gene
expression profiles.  For  this  reason,  it  is  argued to  be more sensitive  than conventional
methodologies aimed at detecting toxicity [68]. Indeed this was demonstrated in rats ex‐
posed  to  sub-toxic  doses  of  acetaminophen,  where  subtle  changes  in  gene  expression
profile were observed although no histological changes manifested [69]. This boasts well
for toxicogenomics as being able to identify the most sensitive signals of potential hepa‐
totoxicity.  The  authors  did  however  emphasise  the  weight  of  demarcating  toxic  events,
sub-toxic  /  adverse  events,  and adaptive  responses  as  this  will  have  great  influence  on
the outcomes of toxicogenomic studies. The ability to detect responses at a molecular lev‐
el that are not necessarily revealed at phenotypic level makes it possible to address ques‐
tions  about  linearity  of  the  dose-response  curve  at  low  exposure  levels  and  allows  for
more  accurate  determination  of  inflection  points  along  to  dose-response  curve  and
threshold exposure levels [68].  These determinants can play pivotal roles in safety phar‐
macology when selecting dosages for clinical studies. Regarding the predictive power of
genomics, Zhang et al.  [70] were able to achieve 83% accuracy in predicting human DILI
using data obtained from rats. Rats that met Hy’s law were found to express a gene ex‐
pression signature, which led to an 83% accuracy [70]. Unfortunately, toxicogenomics us‐
ing cell cultures and toxicogenomics using rodents do not correlate as well as one would
hope. Following acetaminophen exposure, in vitro  toxicogenomics using primary hepato‐
cytes yielded results comparable to that of in vivo  toxicogenomics regarding acute cellu‐
lar toxicity. However, in vivo  toxicogenomics revealed genetic expression changes due to
an  inflammatory  response,  which  in  vitro  toxicogenomics  failed  to  detect  [71].  This  un‐
earths the stubborn dilemma of  inter-dependent  physiological  systems within an organ‐
ism, which is very difficult to recreate experimentally.
Unlike the genome, the proteome is a dynamic entity that changes as gene activation and
epigenetic factors alter protein expression due to endogenous and exogenous signals and
factors. Studying the proteome allows the surveillance of current cellular events, which can
only be deduced from genomics data. This is probably the greatest disadvantage of toxicoge‐
nomics compared to toxicoproteomics; there are many splice variants, post-translational
modifications and subcellular localizations of the final products originating from genes [72,73]
implying that some degree of extrapolation is necessary when predicting cellular events from
genomics data. When studying the proteome, differential expression such as this can be
detected and this may in fact form part of the solution, rather than part of the problem.
Studying the proteome provides a direct description of cellular functions [74]. Thus far,
toxicoproteomic attempts to predict DILI have demonstrated limited efficacy when performed
in vitro [75]. Toxicoproteomics performed on in vitro cultures have the key advantage that
biologically significant alterations can be monitored without relying on whole animals [76].
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Exposing HepG2 cells to three model hepatotoxins that are known to cause necrotic, steatotic
or cholestatic liver injury, researchers were only able to distinguish cholestatic injury from
untreated controls [75]. The study failed to successfully discern necrotic and steatotic events,
however, the ability to detect adverse cholestatic events in HepG2 cells is noteworthy, as these
cells are not known to form biliary structures in a monolayer but rather present as parenchymal
cells [43]. This implies that morphological studies would not have been able to detect this event
and further suggests that native morphological features may not be required in order to detect /
predict certain types of toxicity when utilising in vitro proteomic approaches.
Perhaps a more integrated approach would eventually prove more fruitful. Researchers
conducted a study in which they characterised methapyrilene-induced hepatotoxicity in rats
employing three profiling technologies simultaneously: genomics, proteomics and metabolo‐
mics [77]. The report demonstrated the possibility and great value of these technologies when
used in an integrative manner, where responses to the toxic insult could be followed from
genetic expression changes, to protein up- / down-regulation, through to changes in the
metabolite profile, which gave a very good indication of where and how the chemical entity
may exert its biochemical action(s). Conducting this type of study on a substantial number of
compounds, both hepatotoxic and not, will yield a vast amount of data on how hepatocytes
react toward challenges with different types of chemical entities and provide insight into which
responses should raise concern and which are harmless. It may also deliver further under‐
standing of the mechanisms by which hepatocyte injury occurs.
One major drawback of all the profiling technologies is that most of the current research has
been carried out in vivo, which is predominantly unwanted in the drug development scenario.
The ultimate goal of predictive toxicology would be to develop techniques that can be used
in vitro. However, it should also be noted that it is highly unlikely that animal studies will be
avoided altogether, at least not for the foreseeable future, which leaves room for in vivo
profiling technologies as adjuvants to conventional safety pharmacology testing. In fact, it may
help justify the use of animals for safety pharmacology testing. It is not impossible to employ
these technologies using in vitro platforms, but more research is necessary to develop and
establish effective methodologies and biomarkers.
4.3. Emerging technologies
The main reason for a lack of in vitro predictive power is the difference in phenotype be‐
tween  perpetual  hepatocyte  monolayers  and  native  in  vivo  hepatocytes.  The  traditional
approach to circumvent this problem was the use of primary hepatocytes, which are con‐
sidered to be the “gold standard” for in vitro  hepatotoxicity studies. Two emerging tech‐
nologies  that  may  offer  alternative  solutions  are  hepatocytes  differentiated  from  stem
cells and 3D culturing techniques.
4.3.1. Stem cell technologies
As all physiological processes take place in a cellular setting, the highest quality of cells should
be used to determine safety and efficacy. This led to the use of stem cells. Stem cells are
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classified as embryonic or adult, which is distinguished by developmental status. Where adult
stem cells are multipotent (yield the cell type from the tissue from which they originate),
embryonic stem cells are pluripotent (can give rise to differentiated cell lineages of all three
germ layers). Stem cells that originate from embryos have a normal diploid karyotype and do
not exhibit donor-dependent variability. The advantage of these cells compared to primary
cells are that they can be maintained in culture for a longer period of time and can be grown
up in large scale, producing high volumes.
The  implementation  of  murine  embryonic  cells  to  predictably  identify  human  develop‐
mental toxins, allowing for early identification of toxicity or candidate compounds in the
discovery pipeline was initiated by ECVAM. Mouse hepatocyte-like cells, which were es‐
tablished from embryonic stem cells  were the first  to be used in hepatotoxicity models.
The efficacy of cell  differentiation and maturation was improved, where the cells gener‐
ated alpha fetoprotein and albumin [78]. Cell characteristics included: 70% expressed the
phenotypical  marker  albumin,  they  metabolized  ammonia,  lidocaine  and  diazepamat
nearly two-thirds the rate of primary mouse hepatocytes. However, the difference in me‐
tabolism between humans and mice is  considerable leading to interspecies extrapolation
problems.  Subsequently  hepatocyte-like  cells  were  differentiated  from  hESC  [79].  These
cells  contained  liver-related  characteristics  such  as;  expression  of  α-fetoprotein,  produc‐
tion of albumin, hepatocyte nuclear factor 4α and induction of CYP450 enzymes,  stored
glycogen and showed uptake of idocyanine green. This was followed by more differenti‐
ated  hepatocyte-like  cells  which  additionally  express  functional  glutathione  transferase
activity at levels comparable to human hepatocytes [80].
The advantages of stem cells in relation to transformed/tumour or primary cells are that the
former possesses normal growth, genetic transformation and genetic composition as well as
uniform physiology and pharmacology [81]. Since stem/progenitor cells can differentiate into
clinically relevant cell types, but still maintain functional similarities to their in vivo counter‐
parts, they allow for safer drugs to be introduced into clinical trials and the market place. Other
advantages of stem cells include; the availability of cell types which were not previously
available and the ability to investigate cellular renewal, regeneration, expansion as well as
differentiation [82]. Stem cells can also be genetically modified using reporter gene construct,
thereby providing specific disease models [83].
As  with  all  technologies,  there  are  still  hurdles  to  overcome with  stem cell  technology.
Many clinically relevant cell types cannot be efficiently differentiated, purified and isolat‐
ed [82]. Human stem cells that reproducibly deliver hepatocytes with predictive pharma‐
cology  results  for  high-throughput  safety  screens  are  limited.  Although  progress  has
been made in the differentiation protocols, scaling cell growth and plating for cell-based
assays,  as  well  as  refining of  these  protocols  in  order  to  ensure  homogeneous  prepara‐
tions  will  continue.  Currently,  panels  of  human embryonic  stem cells  which  reflect  the
wide variation in the population are not available.
Although these hurdles exist, stem cells hold the potential for investigation into metabolic
competence, biotransformation capacity and transformation of exogenous compounds. Also,
the ability to determine human inter-individual differences due to genetic polymorphisms.
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4.3.2. 3D culturing techniques
Although 2D techniques have the advantages of being relatively inexpensive, reproducible,
robust and convenient, they have the chief disadvantage of loss of much of the functionality
of native hepatocytes [84], which raises the question of the relevance of such a model in
predicting DILI. Three-dimensional culturing of hepatocytes is an attempt to imitate an in
vivo environment in order to obtain more innate hepatocyte-like cells, thus producing a more
relevant model to study hepatotoxicity whilst using an in vitro platform.
The sandwich configuration of 3D culturing is frequently used when propagating primary
hepatocytes as  it  has been shown that  maintaining these cells  in this  configuration pro‐
longs their in vitro life-span by promoting cellular junctions, cell-cell and cell-matrix inter‐
actions,  and  maintaining  differentiation  [85-87].  After  seeding  a  sandwich  culture  of
primary hepatocytes, the cells require a recuperation period of > 40 h. During this period
a number of morphological changes occurs as the hepatocytes acclimatise to their new en‐
vironment, one of which is the formation of bile canaliculi [63,88]. The latter highlights a
particular role that 3D culturing techniques may play in predicting cholestatic type DILI.
Cholestatic DILI has been problematic to detect or predict using in vitro systems because
most cell lines do not produce the native biliary structures when propagated in monolay‐
er configuration. HepaRG cells,  differentiated using dimethyl sulphoxide and glucocorti‐
costeroids,  have been reported to form biliary-like structures when grown in 2D format
[52]. Building on the work of Liu et al. [89], Ansede et al. [63] demonstrated that it is pos‐
sible to determine whether drugs may induce cholestasis using primary rat hepatocytes in
the sandwich culture configuration. Deuterated taurocholic acid was used, which is easily
discernable  from endogenous sodium taurocholate  using liquid chromatography/tandem
mass spectrometry, to monitor bile acid transport.  The effect of Ca2+  on hepatocyte tight
junction integrity was exploited in order to discern between hepatic uptake and efflux of
deuterated taurocholic acid.  Using this approach the researchers were able to determine
total  and intracellular bile  acid accumulation,  biliary excretion index and in vitro  biliary
clearance.
A manuscript that unmistakeably illustrates the important role that 3D culturing techni‐
ques can play in drug development is Lee et al. [90]. Using sandwich-cultured rat primary
hepatocytes, the authors were able to elucidate the hepatoprotective effect of dexametha‐
sone  on  tabectedin-induced  hepatotoxicity.  At  the  time  of  the  study,  trabectedin  was  a
promising new antineoplastic agent showing activity against various cancers at nanomo‐
lar concentrations and which had already reached phase II clinical trials, but was found to
have dose-limiting hepatotoxic side-effects. The report highlights the fact that experiments
using primary rat hepatocytes cultured in a monolayer configuration were unable to repli‐
cate the known hepatoprotective effect of dexamethasone against trabectedin-induced tox‐
icity. The reason for this was the lack of hepatobiliary functionality of the hepatocytes in
monolayer configuration, and explains why the sandwich configuration was able to show
that  dexamethasone  protected  hepatocytes  by  restoring  normal  hepatobiliary  function.
This demonstrates that 3D culturing techniques hold the key to predicting different sub‐
types of DILI such as hepatocellular necrosis and cholestatic injury. Whether or not simi‐
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lar  experiments  would  prove  successful  when  using  HepaRG  cells  is  still  to  be
determined.
It is difficult for nutrients to reach, and for waste products to be removed from hepatocytes in
a traditional sandwich configuration because the cells are entrapped in a thick extracellular
matrix. The perfusion sandwich culture [91] and entrapment between ultra-thin porous silicon
membranes technologies [92] were developed to surmount these complications. In addition to
maintaining hepatobiliary function, both these methods claim added predictive capabilities
for DILI as demonstrated through increased sensitivity to acetaminophen toxicity due to
preserved metabolic enzyme functionality. Still, even with these improved methods, the life-
span of these primary hepatocytes remains limited, which restricts the use of such methods
on a large scale.
Other  3D culturing methods are  mainly based on bio-artificial  liver  bioreactors  that  are
aimed  at  developing  extracorporeal  liver  support  systems  for  patients  with  acute  liver
failure. In the past, such bioreactors were based on adult hepatocytes and proved unsuc‐
cessful  because the hepatocytes failed to proliferate [93].  The latest  of  these that  are be‐
ing explored for its use in drug toxicity testing is the four-compartment perfusion model.
Cells are contained in one of the four compartments,  the remaining three compartments
comprises three independent but interwoven artificial capillary bundles that form the ca‐
pillary bed in which the cells are housed. Cells are derived from hESCs and currently re‐
search  is  being  carried  out  to  obtain  the  optimal  protocol  for  differentiating  these  cells
into mature hepatocytes that closely resemble innate hepatocytes. This research project is
headed by the EU Vitrocellomics project [94].
Anchorage-free 3D culturing methods result in the formation of small hepatocyte aggre‐
gates known as spheroids. There are different ways to induce the formation of spheroids
including continuously-stirred bioreactors [94], the rocked suspension technique [95] and
rotating  wall  bioreactors  [96].  Initial  experimentation  demonstrated  that,  between  sphe‐
roids and monolayers, there was indeed differential toxicity induced by 7 day methotrex‐
ate  exposure.  It  was  thought  that  this  was  due  to  preservation  of  hepatocyte
functionality, but could also have been due to lack of the test compound to penetrate the
spheroidal  structure  [97].  More  than  a  decade  later  it  is  well  known  that  liver-specific
functions  like  albumin  and  urea  synthesis  and  metabolic  activities  are  maintained  for
prolonged periods of up to 21 days [94].  In time, spheroids deposit an extracellular ma‐
trix consisting of  laminin,  fribronectin and collagen,  which encapsulates each individual
spheroid.  These  structures  also  preserve  histotypical  cytarchitechture,  intercellular  con‐
tacts  (gap junctions)  and biliary canaliculi  [98].  Moreover,  when hepatocytes  grown un‐
der these conditions are encapsulated in alginate  polymers,  albumin and urea synthesis
doubles and phase I and II metabolic activities are also elevated. This may be attributed
to the bulk added to the extracellular matrix,  provided by the alginate polymers,  which
protects  the  hepatocytes  from  shear  stresses  under  hydrodynamical  conditions  [94].  A
setback  of  this  technique  is  the  difficulty  of  obtaining  spheroids  that  are  of  a  specific
mean diameter (100 μm) and batches of spheroids that are all similar in size. This is nec‐
essary as necrotic cell death may occur at the centre of spheroids if the diameter of these
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aggregates  exceeds  approximately  300  μm.  The reason for  this  is  lack  of  oxygen perfu‐
sion to cells located in the central region of spheroids that are too large in size [99].
Recently researchers attempted to predict hepatotoxicity employing hepatocyte spheroids
developed from an immortalised cell line, a HepG2 derivative (C3A), instead of primary
hepatocytes  [96].  The study emphasizes the value of  proper dosing during toxicity test‐
ing.  In the study spheroids were not exposed to a set  concentration of  drug in the cul‐
ture medium for individual experiments. Rather, the concentration of drug in the culture
medium was adjusted with each experiment to mimic in vivo  dosing practices where the
amount of drug was altered according to the amount of protein present in the bioreactor
i.e. dosages were reported as mg drug / mg protein. Using this approach the researchers
were able to obtain more accurate predictions of lethal human blood concentrations com‐
pared to conventional 2D culturing techniques.
5. Future directions
It would be fair to say that 2D culturing techniques have predominated since the inception of
research on artificially cultured cells and as such numerous ways have been developed to
analyse cells in the 2D format. Amongst others, this is one of the key advantages that 2D
culturing techniques have over 3D culturing techniques, demonstrated by the multiple
parameters that can be simultaneously assessed using HCS. Currently, this is not possible
when using 3D cultures as all cells are not in the same pane and cannot be examined individ‐
ually. On the other hand, the relevance of 2D culture models is questionable when compared
to 3D models that more closely resemble their native counterparts. Various reports have shown
that 3D culturing methods are superior to 2D cultures in detecting or predicting certain types
of DILI, especially cholestatic injury as 2D models do not express the necessary morphology
to study this. Profiling technologies may be able to breach the chasm between 2D and 3D
culture models because it is applicable to both scenarios and have been shown to distinguish
cholestatic hepatotoxins even when applied to 2D cultures.
The proteome represents current events on a cellular level and 3D cultures are better depictions
of innate hepatocytes. Therefore, proteomic investigations that are based on 3D cultures, dosed
using in vivo practices (mg drug/ mg protein), and are similar in size to the large DILI prediction
studies that have been conducted on 2D cultures may prove exceedingly valuable in providing
researchers with a set of protein biomarkers that can successfully predict DILI in humans. A
substantial amount of research is necessary into this field of interest.
What is missing from current literature is the assessment of 3D cultures to express / secrete
biomarkers that are currently used in the clinical setting, i.e. ALT, AST, ALP and bilirubin, and
how these respond following challenge with various drugs. Research into this area may
uncover possible accurate extrapolations that can be validated for use in predicting DILI. For
instance, it is possible that 3D cultures secrete sufficient quantities of ALT and bilirubin to be
measured in the surrounding culture medium. Maybe these markers will fluctuate in a way
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similar to what would occur in the in vivo setting and it may therefore be possible to assess the
criteria for, and apply, Hy’s law on an in vivo-like in vitro system.
The in vitro technologies necessary to shift the detection and prediction of candidate drugs that
may cause DILI from the clinical phases of drug development to the early pre-clinical phase,
is available at present. There are various types of in vitro technologies available and each has
its own unique advantages and disadvantages. For this reason, different approaches may be
able to identify and predict certain types of DILI better than others and vice versa. Therefore,
an integrated approach based on multiple models may be a step in the right direction if an in
vitro platform is desired. Cultures of hepatocyte spheroids may be convenient in this scenario.
At the end of an experiment, individual spheroids from the same bioreactor can be examined
using different technologies (some can be used for profiling, others for microscopic evaluation,
and still others for fluorescent analyses following digestion), which would make the results
truly comparable in that all the spheroids would be subjected to the exact same conditions.
Work is necessary to incorporate the available methods into a standard set of tests, com‐
prising of different tiers,  which generate data that can be interpreted as a whole,  to aid
the critical  ‘go’ /  ‘no-go’ decision (the earlier,  the better).  Such a set of experiments will
greatly improve lead prioritization before astronomical amounts of funds are invested in‐
to a  particular  potential  drug.  In the long run this  will  increase the productivity of  the
entire  drug development process by alleviating some of  the financial  pressures and im‐
proving time-scales from drug discovery to marketing as less time is spent on candidates
that will eventually fail in the clinical phases. Finally, it should aid regulatory authorities
in granting approval and provide safer drugs for consumers.
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